Current Oncology Reports

, Volume 14, Issue 5, pp 441–448

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

  • Michael A. Postow
  • Omid Hamid
  • Richard D. Carvajal
Melanoma (K Margolin, Section Editor)

Abstract

Mucosal melanoma represents a rare subtype of melanoma with distinct biological, clinical, and management considerations. Knowledge regarding optimal treatment strategies for mucosal melanoma is limited and based primarily upon small case series and single-institution, retrospective analyses. Surgery remains the standard of care for loco-regional management, but the common presence of multifocal disease and the high rate of distant recurrence should be considered before pursuing aggressive surgical interventions associated with inherent significant morbidity. The role of sentinel lymph node biopsy and lymph node dissection remains unclear. Radiotherapy has not been shown to improve overall survival but may reduce the rate of local recurrence. Significant advances in the treatment of metastatic disease have been made with novel immunotherapeutic agents, the discovery of KIT and BRAF mutations and the development of targeted agents that inhibit these oncogenic pathways.

Keywords

Mucosal melanoma c-KIT Head and neck melanoma Anorectal melanoma Vulvovaginal melanoma Ipilimumab Vemurafenib Imatinib 

References

Papers of particular interest, published recently, have been highlighted as: •  Of importance •• Of major importance

  1. 1.
    McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin. 2012;62:10–29.CrossRefGoogle Scholar
  3. 3.
    Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56:828–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Garland CF, Garland FC, Gorham ED. Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates. Ann Epidemiol. 2003;13:395–404.PubMedCrossRefGoogle Scholar
  6. 6.
    Takagi M, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan. With special reference to mucosal melanosis. Cancer. 1974;34:358–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Axell T, Hedin CA. Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Scand J Dental Res. 1982;90:434–42.Google Scholar
  8. 8.
    Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol. 2003;88:45–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Verschraegen CF, Benjapibal M, Supakarapongkul W, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer. 2001;11:359–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Watanabe J, Yamamoto S, Souma T, et al. Primary malignant melanoma of the male urethra. Int J Urol. 2000;7:3513.CrossRefGoogle Scholar
  11. 11.
    Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Bachar G, Loh KS, O'Sullivan B, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck. 2008;30:1325–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer. 2004;100:1657–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol. 2003;27:594–611.PubMedCrossRefGoogle Scholar
  15. 15.
    Pfister DG, Ang KK, Brizel DM, et al. Mucosal melanoma of the head and neck. JNCCN. 2012;10:320–38.PubMedGoogle Scholar
  16. 16.
    Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol. 2006;132:73–8.CrossRefGoogle Scholar
  17. 17.
    Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol. 2009;135:1219–24.CrossRefGoogle Scholar
  18. 18.
    Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck. 1991;13:22–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Starek I, Koranda P, Benes P. Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res. 2006;16:423–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J. 2007;13:217–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRefGoogle Scholar
  22. 22.
    Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80:1373–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008;30:1543–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Wu AJ, Gomez J, Zhung JE, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol. 2010;33:281–5.PubMedGoogle Scholar
  26. 26.
    Cote TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res. 2009;19:58–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Iddings DM, Fleisig AJ, Chen SL, et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing 3 decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol. 2010;17:40–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum. 1995;38:146–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006;244:1012–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma. Br J Surg. 2004;91:1183–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002;20:4555–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Kelly P, Zagars GK, Cormier JN, et al. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer. 2011;117:4747–55.Google Scholar
  33. 33.
    Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlof B, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer. 1999;86:1273–84.PubMedCrossRefGoogle Scholar
  34. 34.
    Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol. 1994;171:1225–30.PubMedGoogle Scholar
  35. 35.
    Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol. 2007;110(2 Pt 1):296–301.PubMedCrossRefGoogle Scholar
  36. 36.
    Piura B, Rabinovich A, Yanai-Inbar I. Primary malignant melanoma of the vagina: case report and review of literature. Eur J Gynaecol Oncol. 2002;23:195–8.PubMedGoogle Scholar
  37. 37.
    Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 1970;120:425–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Frumovitz M, Etchepareborda M, Sun CC, et al. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010;116:1358–65.PubMedCrossRefGoogle Scholar
  39. 39.
    Suwandinata FS, Bohle RM, Omwandho CA, et al. Management of vulvar melanoma and review of the literature. Eur J Gynaecol Oncol. 2007;28:220–4.PubMedGoogle Scholar
  40. 40.
    de Hullu JA, Hollema H, Hoekstra HJ, et al. Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer. 2002;94:48691.Google Scholar
  41. 41.
    Dhar KK, Das N, Brinkman DA, et al. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of 2 cases and review of the literature. Int J Gynecol Cancer. 2007;17:720–3.PubMedCrossRefGoogle Scholar
  42. 42.
    van Geel AN, den Bakker MA, Kirkels W, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology. 2007;70:143–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Heath DI, Womack C. Primary malignant melanoma of the gall bladder. J Clin Pathol. 1988;41:1073–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Habeck JO. Primary malignant melanoma of the gallbladder. Case report and literature review. Zentralbl Pathol. 1993;139:367–71.PubMedGoogle Scholar
  45. 45.
    Lam KY, Law S, Wong J. Malignant melanoma of the oesophagus: clinicopathological features, lack of p53 expression and steroid receptors and a review of the literature. Eur J Surg Oncol. 1999;25:168–72.PubMedCrossRefGoogle Scholar
  46. 46.
    Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet. 2009;10:516–21.CrossRefGoogle Scholar
  47. 47.
    Blecker D, Abraham S, Furth EE, et al. Melanoma in the gastrointestinal tract. Am J Gastroenterol. 1999;94:3427–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Yi JH, Yi SY, Lee HR, et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21:223–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Bartell HL, Bedikian AY, Papadopoulos NE, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck. 2008;30:1592–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004;100:1478–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res. 2004;14:517–20.PubMedCrossRefGoogle Scholar
  52. 52.
    Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol. 2007;25:5426–34.PubMedCrossRefGoogle Scholar
  53. 53.
    Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748–54.PubMedCrossRefGoogle Scholar
  54. 54.
    •• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. First phase III study to show an improvement in overall survival for patients with metastatic melanoma. Results of this study contributed to the US FDA approval of ipilimumab..PubMedCrossRefGoogle Scholar
  55. 55.
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. Second phase III study to demonstrate an improvement in overall survival for patients who received ipilimumab compared to those who did not..PubMedCrossRefGoogle Scholar
  56. 56.
    •• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. First demonstration of the overall survival benefit of vemurafenib, the targeted inhibitor of oncogenic BRAF..PubMedCrossRefGoogle Scholar
  57. 57.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRefGoogle Scholar
  58. 58.
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRefGoogle Scholar
  59. 59.
    Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878–90.PubMedCrossRefGoogle Scholar
  60. 60.
    Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Rivera RS, Nagatsuka H, Gunduz M, et al. C-KIT protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 2008;452:27–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046–51.PubMedCrossRefGoogle Scholar
  63. 63.
    •• Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–34. Phase II study showing the efficacy of imatinib for patients with KIT genetic aberrations, including patients with mucosal melanoma who achieved durable partial and complete responses..PubMedCrossRefGoogle Scholar
  64. 64.
    •• Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J Clin Oncol. 2011;29:2904–9. Phase II study showing the efficacy of imatinib for patients with KIT genetic aberrations..PubMedCrossRefGoogle Scholar
  65. 65.
    Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18:1457–63.PubMedCrossRefGoogle Scholar
  66. 66.
    Si L, Xu X, Kong Y, et al. Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol. 2012;30:e37–40.PubMedCrossRefGoogle Scholar
  67. 67.
    Tsao H, Zhang X, Fowlkes K, et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000;60:1800–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Michael A. Postow
    • 1
  • Omid Hamid
    • 2
  • Richard D. Carvajal
    • 1
    • 3
  1. 1.Department of MedicineWeill-Cornell Medical College, Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Melanoma Center, Translational Research Institute & ImmunotherapyThe Angeles Clinic and Research InstituteLos AngelesUSA
  3. 3.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations